 Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F the Company, an international biopharmaceutical company, today provides an update on its clinical developments. On February 3, 2020, the Company announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA issued a positive opinion with respect to our submission for the Ameluz label extension for the treatment of actinic keratosis AK on the extremities and trunkneck. In addition, the results of the follow-up phase of the clinical comparison study for daylight PDT with Ameluz and Metvix will be included in the product information SmPC. 